Lee Hyoun Wook, Ha Seung Yeon, Roh Mee Sook
Department of Pathology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.
Department of Pathology, Gachon University of Medicine and Science, Incheon, Korea.
J Cytol. 2021 Jan-Mar;38(1):8-13. doi: 10.4103/JOC.JOC_94_20. Epub 2021 Jan 8.
Subtyping of solitary pulmonary lesion (SPL) in small amount of cytology specimen using a limited panel of immunohistochemistry (IHC) markers is very important to the correct choice of treatment. This study was performed to categorize non-small cell carcinoma-not otherwise specified (NSCC-NOS) on cytology in patients with SPL, especially with regard to the incidence of metastatic cancer.
We reviewed 91 cases, in which a precise morphology-based, lineage-specific IHC-aided subtyping was not possible, that qualified as NSCC-NOS on cytology. A stepwise clinical approach and IHC of organ-specific markers was performed on each cell block (CB) to exclude metastasis from extrapulmonary malignancies.
Of the 91 evaluated cases, 65 (71.4%) were diagnosed as non-small cell lung carcinoma (NSCLC)-NOS, 24 (26.4%) were metastatic cancer, and the remaining 2 (2.2%) had undetermined diagnoses. The most frequent primary tumor site was the colorectum (41.7%), followed by breast (20.8%), kidney (8.3%), and then stomach, duodenum, liver, pancreas, gallbladder, prostate, and skin (4.2% each, 1 of 24). Moreover, we found that 7 of the 24 patients with metastatic cancer had a history of extrapulmonary malignancy that was unknown at the time of cytology-based diagnosis.
These results underscored the need for accurate and stepwise clinical correlation to rule out the possibility of pulmonary metastasis from other sites and appropriate but judicious IHC (i.e., CDX2) on CB for SPL to increase refinement of the cytology diagnosis of NSCC-NOS.
使用有限的免疫组织化学(IHC)标志物对少量细胞学标本中的孤立性肺病变(SPL)进行亚型分类对于正确选择治疗方法非常重要。本研究旨在对SPL患者的细胞学非小细胞癌,未另行规定(NSCC-NOS)进行分类,特别是关于转移性癌的发生率。
我们回顾了91例病例,这些病例无法基于精确形态学进行谱系特异性IHC辅助亚型分类,在细胞学上被归类为NSCC-NOS。对每个细胞块(CB)采用逐步临床方法和器官特异性标志物的IHC来排除肺外恶性肿瘤的转移。
在91例评估病例中,65例(71.4%)被诊断为非小细胞肺癌(NSCLC)-NOS,24例(26.4%)为转移性癌,其余2例(2.2%)诊断未明。最常见的原发肿瘤部位是结肠直肠(41.7%),其次是乳腺(20.8%)、肾脏(8.3%),然后是胃、十二指肠、肝脏、胰腺、胆囊、前列腺和皮肤(各4.2%,24例中的1例)。此外,我们发现24例转移性癌患者中有7例在基于细胞学诊断时具有未知的肺外恶性肿瘤病史。
这些结果强调了需要进行准确且逐步的临床关联,以排除其他部位肺转移的可能性,并对SPL的CB进行适当但审慎的IHC(即CDX2),以提高NSCC-NOS细胞学诊断的准确性。